<DOC>
	<DOCNO>NCT00046488</DOCNO>
	<brief_summary>To determine side effect clinical effect administration investigational product , IDEC-152 ( antibody CD23 important protein leukemia cell certain cell body 's immune system ) , CLL patient population .</brief_summary>
	<brief_title>Safety Efficacy IDEC-152 Treatment Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Signed IRBapproved informed consent . Greater 18 year age Proof CD23+ CLL small lymphocytic lymphoma ( SLL ) Progressive disease least 1 course chemotherapy Acceptable hematologic status , liver function , renal function , pulmonary function Patients reproductive potential must agree follow accepted birth control method treatment 3 month completion treatment Previous exposure IDEC152 antiCD23 antibody Presence HIV infection AIDS Serious nonmalignant disease Active uncontrolled bacterial , viral fungal infection . Clinically active autoimmune disease Pregnant currently breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Chronic Lymphoblastic Leukemia</keyword>
	<keyword>Leukemia , Lymphoblastic , Chronic</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>